Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation

Herantis’s Parkinson’s Therapy Passes Preliminary Trial Safety Evaluation
An independent review board has found Herantis Pharma’s Parkinson’s therapy safe, paving the way for a Phase 1/2 clinical trial in Sweden to continue. The board based its decision on the safety results seen in the first few patients treated with cerebral dopamine neurotrophic factor, or CDNF, at Karolinska University Hospital in Stockholm. Its findings mean Herantis can recruit patients at two other study sites — Helsinki University Hospital ... read more
Source: Parkinson’s News TodayPublished on 2018-02-20By Iqra Mumal